Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v6-FR Version v1-EN
Language French English
Date Updated 2022-10-12 2022-08-16
Drug Identification Number 02422956 02422956
Brand name ALPROLIX ALPROLIX
Common or Proper name ALPROLIX 3000 ALPROLIX 3000
Company Name SANOFI-AVENTIS CANADA INC SANOFI-AVENTIS CANADA INC
Ingredients RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN RECOMBINANT HUMAN COAGULATION FACTOR IX, FC FUSION PROTEIN
Strength(s) 3000UNIT 3000UNIT
Dosage form(s) POWDER FOR SOLUTION KIT POWDER FOR SOLUTION KIT
Route of administration INTRAVENOUS INTRAVENOUS INTRAVENOUS INTRAVENOUS
Packaging size 1 VIAL & 5 ML PREFILLED DILUENT SYRINGE 1 VIAL & 5 ML PREFILLED DILUENT SYRINGE
ATC code B02BD B02BD
ATC description VITAMIN K AND OTHER HEMOSTATICS VITAMIN K AND OTHER HEMOSTATICS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2022-08-12 2022-08-12
Estimated end date 2022-09-26 2022-09-09
Actual end date 2022-10-06
Shortage status Resolved Actual shortage
Tier 3 Status No No
Company comments The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date. The availability date represents estimated availability at the main Sanofi warehouse. Availability dates at a customer’s usual distributor warehouse may vary. Pharmacies are invited to communicate with their preferred distributor to obtain the product availability date.
Health Canada comments